Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy

Aim. To assess the role of stimulating growth factor 2 (ST-2) and galectin-3 in predicting the ventricular tachyarrhythmias (VTA) in patients with coronary artery disease (CAD) and left ventricular ejection fraction (LVEF) <35%.Material and methods. The study included 40 patients (men, 36 (90...

Full description

Saved in:
Bibliographic Details
Main Authors: T. A. Atabekov, R. E. Batalov, S. I. Sazonova, A. M. Gusakova, S. N. Krivolapov, M. S. Khlynin, S. V. Popov
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2021-05-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/2676
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849250369872330752
author T. A. Atabekov
R. E. Batalov
S. I. Sazonova
A. M. Gusakova
S. N. Krivolapov
M. S. Khlynin
S. V. Popov
author_facet T. A. Atabekov
R. E. Batalov
S. I. Sazonova
A. M. Gusakova
S. N. Krivolapov
M. S. Khlynin
S. V. Popov
author_sort T. A. Atabekov
collection DOAJ
description Aim. To assess the role of stimulating growth factor 2 (ST-2) and galectin-3 in predicting the ventricular tachyarrhythmias (VTA) in patients with coronary artery disease (CAD) and left ventricular ejection fraction (LVEF) <35%.Material and methods. The study included 40 patients (men, 36 (90,0%); median age, 64,5 [57,5; 68,5] years) with CAD, NYHA class IIIII heart failure, LVEF <35%, indications for implantable cardioverter defibrillator (ICD) (primary prevention of sudden cardiac death). Prior to ICD implantation, patients were measured for serum ST-2 and galectin-3 levels. For 18 months, patients were assessed for arrhythmic events recorded in the ICD memory.Results. The 1st group consisted of 10 (25,0%) patients who had VTA episodes, arrested by antitachycardia pacing or shock during 18-month follow-up. The 2nd group consisted of 30 (75,0%) patients without VTA episodes. It was found that ST-2 concentration >22,48 ng/ml (p=0,02) and galectin-3 >10,95 ng/ml (p=0,009) corresponded to appropriate ICD discharge. Multivariate ROC analysis demonstrated that the only independent predictor of VTA was ST-2 elevation (odds ratio, 1,11; 95% CI, 1,01-1,21; p=0,023).Conclusion. An increase in the concentration of both ST-2 >22,48 ng/ml and galectin-3 >10,95 ng/ml had a high predictive value in assessing the VTA risk in patients with ischemic cardiomyopathy. In multivariate analysis, an increase in ST-2 >22,48 ng/ml was an independent predictor of VTA.
format Article
id doaj-art-5e88d2ed8c084553923236a17cdc4c57
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 2021-05-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-5e88d2ed8c084553923236a17cdc4c572025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252021-05-0120310.15829/1728-8800-2021-26762248Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathyT. A. Atabekov0R. E. Batalov1S. I. Sazonova2A. M. Gusakova3S. N. Krivolapov4M. S. Khlynin5S. V. Popov6Cardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterCardiology Research Institute, Tomsk National Research Medical CenterAim. To assess the role of stimulating growth factor 2 (ST-2) and galectin-3 in predicting the ventricular tachyarrhythmias (VTA) in patients with coronary artery disease (CAD) and left ventricular ejection fraction (LVEF) <35%.Material and methods. The study included 40 patients (men, 36 (90,0%); median age, 64,5 [57,5; 68,5] years) with CAD, NYHA class IIIII heart failure, LVEF <35%, indications for implantable cardioverter defibrillator (ICD) (primary prevention of sudden cardiac death). Prior to ICD implantation, patients were measured for serum ST-2 and galectin-3 levels. For 18 months, patients were assessed for arrhythmic events recorded in the ICD memory.Results. The 1st group consisted of 10 (25,0%) patients who had VTA episodes, arrested by antitachycardia pacing or shock during 18-month follow-up. The 2nd group consisted of 30 (75,0%) patients without VTA episodes. It was found that ST-2 concentration >22,48 ng/ml (p=0,02) and galectin-3 >10,95 ng/ml (p=0,009) corresponded to appropriate ICD discharge. Multivariate ROC analysis demonstrated that the only independent predictor of VTA was ST-2 elevation (odds ratio, 1,11; 95% CI, 1,01-1,21; p=0,023).Conclusion. An increase in the concentration of both ST-2 >22,48 ng/ml and galectin-3 >10,95 ng/ml had a high predictive value in assessing the VTA risk in patients with ischemic cardiomyopathy. In multivariate analysis, an increase in ST-2 >22,48 ng/ml was an independent predictor of VTA.https://cardiovascular.elpub.ru/jour/article/view/2676sudden cardiac deathventricular tachyarrhythmiacardioverter-defibrillator6-minute walk testst-2galectin-3left ventricular ejection fraction
spellingShingle T. A. Atabekov
R. E. Batalov
S. I. Sazonova
A. M. Gusakova
S. N. Krivolapov
M. S. Khlynin
S. V. Popov
Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
Кардиоваскулярная терапия и профилактика
sudden cardiac death
ventricular tachyarrhythmia
cardioverter-defibrillator
6-minute walk test
st-2
galectin-3
left ventricular ejection fraction
title Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
title_full Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
title_fullStr Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
title_full_unstemmed Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
title_short Role of stimulating growth factor 2 and galectin-3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
title_sort role of stimulating growth factor 2 and galectin 3 in predicting the ventricular tachyarrhythmias in patients with ischemic cardiomyopathy
topic sudden cardiac death
ventricular tachyarrhythmia
cardioverter-defibrillator
6-minute walk test
st-2
galectin-3
left ventricular ejection fraction
url https://cardiovascular.elpub.ru/jour/article/view/2676
work_keys_str_mv AT taatabekov roleofstimulatinggrowthfactor2andgalectin3inpredictingtheventriculartachyarrhythmiasinpatientswithischemiccardiomyopathy
AT rebatalov roleofstimulatinggrowthfactor2andgalectin3inpredictingtheventriculartachyarrhythmiasinpatientswithischemiccardiomyopathy
AT sisazonova roleofstimulatinggrowthfactor2andgalectin3inpredictingtheventriculartachyarrhythmiasinpatientswithischemiccardiomyopathy
AT amgusakova roleofstimulatinggrowthfactor2andgalectin3inpredictingtheventriculartachyarrhythmiasinpatientswithischemiccardiomyopathy
AT snkrivolapov roleofstimulatinggrowthfactor2andgalectin3inpredictingtheventriculartachyarrhythmiasinpatientswithischemiccardiomyopathy
AT mskhlynin roleofstimulatinggrowthfactor2andgalectin3inpredictingtheventriculartachyarrhythmiasinpatientswithischemiccardiomyopathy
AT svpopov roleofstimulatinggrowthfactor2andgalectin3inpredictingtheventriculartachyarrhythmiasinpatientswithischemiccardiomyopathy